Abstract
Objective: The aim of the present study was to investigate whether the genetic polymorphism of CYP2C19 plays a role in susceptibility to bronchial asthma. Subjectsand Methods: 104 healthy individuals who visited our hospital, including hospital staff, and 97 patients with bronchial asthma (62 atopic and 35 nonatopic) participated in this study. CYPC19*2 and CYP21C9*3 alleles were detected by using LightCycler and CYP2C19 mutation detection kits by real-time PCR with LightCycler. Results: The CYP2C19*3 genotype was found to be the wild type in all cases, and in the control group, the CYP2C19*2 heterozygous genotype had a 2.46-fold increased risk of bronchial asthmacompared with the CYPC19*2 homozygous wild genotype in the control group(p = 0.01, OR = 2.46, 95% CI 1.24–4.88). Conclusion: Our data suggest that the CYP2C19*2 heterozygous genotype may be involved in the development of bronchial asthma.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
